CR or mCR in 86% of patients within the first 12 months - Venetoclax-resistant secondary AML transformed from CMML responds to lenzilumab BURLINGAME, CA / ACCESS Newswire / November 4, 2025 / Taran ...

Phase 1a of the trial examined dose escalation of IO-202 as a monotherapy and in combination with azacitidine. Phase 1b of ...

"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...

– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...

The regimen of bexmarilimab and azacitidine (Vidaza) demonstrated a highly promising efficacy profile with a manageable ...

Aptose Biosciences Inc. (($APTOF)) announced an update on their ongoing clinical study. Aptose Biosciences Inc. is conducting a clinical study ...

BOSTON, Dec. 9, 2024 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today ...

Leukemia symptoms include fatigue, weakness, chest pain, shortness of breath, bleeding, bruising, and increased infection risk due to altered blood cell counts. Recent leukemia treatment advancements ...

Phase II/III Trial of Etoposide and High-Dose Ifosfamide in Newly Diagnosed Metastatic Osteosarcoma: A Pediatric Oncology Group Trial PURPOSE: We report the first large prospective study of children ...

BEXAR COUNTY, Texas – These days, rising costs are not only a reality for everyday necessities. The cost of health care, including the life-saving treatment for various blood cancers, has also been on ...